The European Commission has authorised Arexvy, the first vaccine to protect adults aged 60 and over, against lower respiratory tract disease caused by respiratory syncytial virus (RSV) "I now encourage Member States to capitalise swiftly on this authorisation and define national vaccination strategies," says EU Health Commissioner Stella Kyriakides. RSC causes about 250,17 hospitalizations and 65,<> deaths each year in people aged <> and over in Europe, according to the European Commission.